Efficient Scaling up EV‐AAVs Production via Cellular Nanoporation for Familial Hypercholesterolaemia Therapy
Journal of Extracellular Vesicles · 2025
DOI: 10.1002/jev2.70186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2025. Verfasst von Yuting Yan und 20 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Pluripotent Stem Cells in Cardiac Repair and Regeneration, State Key Laboratory of Cardiovascular Disease, National Center for Card…. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Dependovirus, Genetic Therapy, Extracellular Vesicles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, National High-Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Adeno‐associated virus (AAV)–mediated gene therapies face critical clinical limitations, including immune‐mediated neutralization by pre‐existing antibodies and dose‐dependent hepatotoxicity. Extracellular vesicle‐encapsulated AAVs (EV‐AAVs) offer a promising solution by shielding AAVs from antibody recognition, yet existing production methods remain inefficient and impractical for clinical application. Here, we developed a cellular nanoporation (CNP) platform that enables scalable, high‐yield generation of EV‐AAVs, achieving an approximately 11‐fold increase in production efficiency compared with conventional methods. In LDLR‐deficient murine models with pre‐existing neutralizing antibodies (1:200), EV‐AAV‐LDLR at half the standard AAV dose robustly restored hepatic LDL receptor expression and attenuated atherosclerosis progression. Notably, EV‐AAV exhibited superior immune evasion capabilities, maintaining 2.3‐fold higher hepatic transduction efficiency than conventional AAV upon secondary dosing due to antibody shielding. Importantly, EV‐AAV therapy markedly reduced hepatotoxicity, with serum AST/ALT levels comparable to saline‐treated controls, thereby overcoming a critical safety barrier of high‐dose AAV treatment. These results demonstrate CNP as a clinically translatable platform for scalable EV‐AAV manufacturing, enabling effective multi‐dose regimens while overcoming key immunological and toxicity barriers in liver‐directed gene therapy for familial hypercholesterolaemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Pluripotent Stem Cells in Cardiac Repair and Regeneration, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Un…
- State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences, Fuwai Hospital, Shenzhen, China.
- Department of Cardiology, Heart Center of Fujian Province, Fujian Medical University Union Hospital, Fujian Medical University Heart Center, Fuzhou, Fujian, China.
- Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science, Suzhou Medical College, Soochow University, Suzhou, Jiangsu, China.
- School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.
- Division of Pediatric Cardiology, Department of Pediatric Medicine, The Seventh Medical Center of Chinese PLA General Hospital, Beijing, China.
ORCID-Profile: Feng Lan
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- National High-Level Hospital Clinical Research Funding
- CAMS Innovation Fund for Medical Sciences
- Shenzhen Fundamental Research Program
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
- China Postdoctoral Science Foundation
- Shenzhen High-level Hospital Construction Fund , National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital
Zitieren
APA
Yan, Y., You, Y., Ma, S., Yi, H., Chen, G., Ni, J., Chen, C., Ke, W., Li, L., Bai, R., Ran, Y., Lu, W., Zhu, M., Zhang, Y., Dai, J., Qi, M., Lan, F., Lee, A. S., Zhang, R., …, & Chen, Z. (2025). Efficient Scaling up EV‐AAVs Production via Cellular Nanoporation for Familial Hypercholesterolaemia Therapy. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70186
Vancouver
Yan Y, You Y, Ma S, Yi H, Chen G, Ni J, et al. Efficient Scaling up EV‐AAVs Production via Cellular Nanoporation for Familial Hypercholesterolaemia Therapy. Journal of Extracellular Vesicles. 2025. doi:10.1002/jev2.70186
BibTeX
@article{Yan2025,
author = {Yan, Yuting and You, Yi and Ma, Shuhong and Yi, Hui and Chen, Guangduo and Ni, Jie and Chen, Changyan and Ke, Wenyu and Li, Lingying and Bai, Rui and Ran, Yuqing and Lu, Wenjing and Zhu, Min and Zhang, Yongshuai and Dai, Jing and Qi, Man and Lan, Feng and Lee, Andrew S and Zhang, Ran and Liu, Xujie and Chen, Zhaoyang},
title = {Efficient Scaling up EV‐AAVs Production via Cellular Nanoporation for Familial Hypercholesterolaemia Therapy},
journal = {Journal of Extracellular Vesicles},
year = {2025},
doi = {10.1002/jev2.70186}
}
EUVIMED